查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1819886

泌尿生殖药物市场报告（按适应症、产品和地区）2025-2033

Genitourinary Drugs Market Report by Indication, Product, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3个工作天内

价格

2024 年全球泌尿生殖药物市场规模达 338 亿美元。展望未来， IMARC Group预计到 2033 年市场规模将达到 398 亿美元，2025-2033 年期间的成长率 (CAGR) 为 1.8%。

泌尿生殖系统包括肾臟、输尿管、膀胱、尿道和生殖器官，在生殖和排出体内废物方面发挥至关重要的作用。其功能可能因先天畸形、医源性损伤、癌症、创伤、感染、肾积水和发炎而受损。由于患有这些疾病的人数不断增加，全球对泌尿生殖药物的需求也增加。泌尿生殖药物有助于治疗生殖器官、排泄系统和泌尿道疾病。它们也用于治疗膀胱痉挛和勃起功能障碍，以及抑制子宫收缩以防止早产。

泌尿生殖药物市场趋势：

泌尿生殖器官损伤风险的增加是影响市场成长的主要因素之一。此外，由于泌尿生殖药物对治疗患有慢性肾衰竭和泌尿道感染的儿科患者有效，其全球销售正在成长。此外，领先的市场参与者正致力于改进製剂技术，以推出有助于治疗对传统化疗和荷尔蒙治疗药物产生抗药性的慢性前列腺癌患者的药物。此外，一些跨国公司 (MNC) 正在与领先的生物製药公司合作，推出下一代疗法，并巩固其市场地位。这与后期临床试验中在研药物数量的大幅增加相结合，共同促进了市场成长。此外，研发 (R&D) 计画资金的增加，以及许多国家政府和非政府机构资助的医疗基础设施的改善，预计将在未来几年推动泌尿生殖药物的需求。

本报告回答的关键问题

  • 全球泌尿生殖药物市场有多大？ 2025-2033年全球泌尿生殖药物市场的预期成长率是多少？
  • 推动全球泌尿生殖药物市场发展的关键因素有哪些？
  • COVID-19 对全球泌尿生殖药物市场有何影响？
  • 根据适应症，全球泌尿生殖药物市场如何分布？
  • 根据产品，全球泌尿生殖药物市场是如何分布的？
  • 全球泌尿生殖药物市场的主要区域有哪些？
  • 全球泌尿生殖药物市场的主要参与者/公司有哪些？
  • 需要更多帮助吗？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球泌尿生殖药物市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依指标

  • 摄护腺癌
  • 卵巢癌
  • 膀胱癌
  • 子宫颈癌
  • 肾癌
  • 性功能障碍
  • 泌尿道感染
  • 尿失禁和膀胱过动症
  • 性传染病
  • 间质性膀胱炎
  • 血尿
  • 良性摄护腺增生

第七章：市场区隔：依产品

  • 泌尿科
  • 荷尔蒙疗法
  • 妇科
  • 抗感染药物
  • 其他的

第八章：市场区隔：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第九章：SWOT分析

第 10 章：价值链分析

第 11 章：波特五力分析

第 12 章：价格分析

第 13 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Allergan plc (AbbVie Inc.)
    • Antares Pharma Inc.
    • AstraZeneca plc
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Genentech Inc. (Roche Holding AG)
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112025A4727

The global genitourinary drugs market size reached USD 33.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 39.8 Billion by 2033, exhibiting a growth rate (CAGR) of 1.8% during 2025-2033.

The genitourinary system includes kidneys, ureters, bladder, urethra, and genital organs, which play a vital role in reproduction and getting rid of waste products from the body. Its functioning can be hampered on account of congenital abnormalities, iatrogenic injuries, cancer, trauma, infections, hydronephrosis, and inflammation. Due to the rising number of individuals suffering from these diseases, there is a rise in the demand for genitourinary drugs across the globe. Genitourinary drugs help treat the reproductive organs, excretory system, and urinary tract conditions. They are also used in the treatment of bladder spasms and erectile dysfunction and suppressing uterine contractions to prevent preterm labor.

Genitourinary Drugs Market Trends:

The increasing risk of genitourinary organ damage represents one of the major factors influencing the growth of the market. Moreover, as genitourinary drugs are effective in treating the pediatric population with chronic kidney failure and urinary tract infections, their sales are increasing around the world. Apart from this, the leading market players are focusing on advancing formulation techniques to introduce drugs that help treat chronic prostate cancer patients who have developed resistance to conventional chemotherapeutic and hormone therapy agents. Furthermore, several multinational companies (MNCs) are collaborating with biopharmaceutical leaders to launch next-generation therapeutics and strengthen their position in the market. This, in confluence with a considerable rise in the number of pipeline drugs in late-stage clinical trials, is contributing to the market growth. Besides this, the increasing funding for research and development (R&D) projects, along with improvements in the healthcare infrastructure sponsored by governing and non-governing agencies of numerous countries, is anticipated to drive the demand for genitourinary drugs in the coming years.

Key Market Segmentation:

Breakup by Indication:

  • Prostate Cancer
  • Ovarian Cancer
  • Bladder Cancer
  • Cervical Cancer
  • Renal Cancer
  • Erectile Dysfunction
  • Urinary Tract Infections
  • Urinary Incontinence and Overactive Bladder
  • Sexually Transmitted Diseases
  • Interstitial Cystitis
  • Hematuria
  • Benign Prostatic Hyperplasia

Breakup by Product:

  • Urological
  • Hormonal Therapy
  • Gynecological
  • Anti-infectives
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Allergan plc (AbbVie Inc.), Antares Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Genentech Inc. (Roche Holding AG), GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

  • 1.How big is the global genitourinary drugs market?
  • 2.What is the expected growth rate of the global genitourinary drugs market during 2025-2033?
  • 3.What are the key factors driving the global genitourinary drugs market?
  • 4.What has been the impact of COVID-19 on the global genitourinary drugs market?
  • 5.What is the breakup of the global genitourinary drugs market based on the indication?
  • 6.What is the breakup of the global genitourinary drugs market based on the product?
  • 7.What are the key regions in the global genitourinary drugs market?
  • 8.Who are the key players/companies in the global genitourinary drugs market?
  • Need more help?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Genitourinary Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Indication

  • 6.1 Prostate Cancer
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Ovarian Cancer
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Bladder Cancer
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Cervical Cancer
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Renal Cancer
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Erectile Dysfunction
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Urinary Tract Infections
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Urinary Incontinence and Overactive Bladder
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast
  • 6.9 Sexually Transmitted Diseases
    • 6.9.1 Market Trends
    • 6.9.2 Market Forecast
  • 6.10 Interstitial Cystitis
    • 6.10.1 Market Trends
    • 6.10.2 Market Forecast
  • 6.11 Hematuria
    • 6.11.1 Market Trends
    • 6.11.2 Market Forecast
  • 6.12 Benign Prostatic Hyperplasia
    • 6.12.1 Market Trends
    • 6.12.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Urological
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Hormonal Therapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Gynecological
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Anti-infectives
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Allergan plc (AbbVie Inc.)
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 SWOT Analysis
    • 13.3.2 Antares Pharma Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
    • 13.3.3 AstraZeneca plc
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
    • 13.3.4 Bayer AG
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Bristol-Myers Squibb Company
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Genentech Inc. (Roche Holding AG)
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 SWOT Analysis
    • 13.3.7 GlaxoSmithKline plc
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Merck & Co. Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Novartis AG
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Pfizer Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Teva Pharmaceutical Industries Ltd.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials

List of Figures

  • Figure 1: Global: Genitourinary Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Genitourinary Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Genitourinary Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Genitourinary Drugs Market: Breakup by Indication (in %), 2024
  • Figure 5: Global: Genitourinary Drugs Market: Breakup by Product (in %), 2024
  • Figure 6: Global: Genitourinary Drugs Market: Breakup by Region (in %), 2024
  • Figure 7: Global: Genitourinary Drugs (Prostate Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 8: Global: Genitourinary Drugs (Prostate Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 9: Global: Genitourinary Drugs (Ovarian Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Genitourinary Drugs (Ovarian Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Genitourinary Drugs (Bladder Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Genitourinary Drugs (Bladder Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Genitourinary Drugs (Cervical Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Genitourinary Drugs (Cervical Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Genitourinary Drugs (Renal Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Genitourinary Drugs (Renal Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Genitourinary Drugs (Erectile Dysfunction) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Genitourinary Drugs (Erectile Dysfunction) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Genitourinary Drugs (Urinary Tract Infections) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Genitourinary Drugs (Urinary Tract Infections) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Genitourinary Drugs (Urinary Incontinence and Overactive Bladder) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Genitourinary Drugs (Urinary Incontinence and Overactive Bladder) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Genitourinary Drugs (Sexually Transmitted Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Genitourinary Drugs (Sexually Transmitted Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Genitourinary Drugs (Interstitial Cystitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Genitourinary Drugs (Interstitial Cystitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Genitourinary Drugs (Hematuria) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Genitourinary Drugs (Hematuria) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Genitourinary Drugs (Benign Prostatic Hyperplasia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Genitourinary Drugs (Benign Prostatic Hyperplasia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Genitourinary Drugs (Urological) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Genitourinary Drugs (Urological) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Genitourinary Drugs (Hormonal Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Genitourinary Drugs (Hormonal Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Genitourinary Drugs (Gynecological) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Genitourinary Drugs (Gynecological) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Genitourinary Drugs (Anti-infectives) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Genitourinary Drugs (Anti-infectives) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Genitourinary Drugs (Other Products) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Genitourinary Drugs (Other Products) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: North America: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: North America: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: United States: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: United States: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Canada: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Canada: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Asia-Pacific: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Asia-Pacific: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: China: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: China: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Japan: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Japan: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: India: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: India: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: South Korea: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: South Korea: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Australia: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Australia: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Indonesia: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Indonesia: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Others: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Others: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Europe: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Europe: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Germany: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Germany: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: France: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: France: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: United Kingdom: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: United Kingdom: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Italy: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Italy: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Spain: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Spain: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Russia: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Russia: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Others: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Others: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Latin America: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Latin America: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Brazil: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Brazil: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Mexico: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Mexico: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Others: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Others: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Middle East and Africa: Genitourinary Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Middle East and Africa: Genitourinary Drugs Market: Breakup by Country (in %), 2024
  • Figure 89: Middle East and Africa: Genitourinary Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 90: Global: Genitourinary Drugs Industry: SWOT Analysis
  • Figure 91: Global: Genitourinary Drugs Industry: Value Chain Analysis
  • Figure 92: Global: Genitourinary Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Genitourinary Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Genitourinary Drugs Market Forecast: Breakup by Indication (in Million USD), 2025-2033
  • Table 3: Global: Genitourinary Drugs Market Forecast: Breakup by Product (in Million USD), 2025-2033
  • Table 4: Global: Genitourinary Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 5: Global: Genitourinary Drugs Market: Competitive Structure
  • Table 6: Global: Genitourinary Drugs Market: Key Players